CRLBF Quote, Financials, Valuation and Earnings

Alnylam Pharmaceuticals, Inc. has a net margin of -13.32% compared to Cresco Labs, Inc.'s net margin of 16.99%. Cresco Labs, Inc.'s return on equity of -13.84% beat Alnylam Pharmaceuticals, Inc.'s return on equity of 107.73%.

Cresco Labs, Inc. has a consensus price target of $2.0000, signalling upside risk potential of 80.18%. On the other hand Alnylam Pharmaceuticals, Inc. has an analysts' consensus of $457.00 which suggests that it could grow by 34.66%. Given that Cresco Labs, Inc. has higher upside potential than Alnylam Pharmaceuticals, Inc., analysts believe Cresco Labs, Inc. is more attractive than Alnylam Pharmaceuticals, Inc..

Cresco Labs, Inc. has a beta of 1.103, which suggesting that the stock is 10.297% more volatile than S&P 500. In comparison Alnylam Pharmaceuticals, Inc. has a beta of 0.350, suggesting its less volatile than the S&P 500 by 65.025%.

Cresco Labs, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Alnylam Pharmaceuticals, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Cresco Labs, Inc. pays -- of its earnings as a dividend. Alnylam Pharmaceuticals, Inc. pays out -- of its earnings as a dividend.

Cresco Labs, Inc. quarterly revenues are $164.9M, which are smaller than Alnylam Pharmaceuticals, Inc. quarterly revenues of $1.1B. Cresco Labs, Inc.'s net income of -$22M is lower than Alnylam Pharmaceuticals, Inc.'s net income of $186.4M. Notably, Cresco Labs, Inc.'s price-to-earnings ratio is -- while Alnylam Pharmaceuticals, Inc.'s PE ratio is 150.36x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Cresco Labs, Inc. is 0.58x versus 12.20x for Alnylam Pharmaceuticals, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

BioMarin Pharmaceutical, Inc. has a net margin of -13.32% compared to Cresco Labs, Inc.'s net margin of -3.91%. Cresco Labs, Inc.'s return on equity of -13.84% beat BioMarin Pharmaceutical, Inc.'s return on equity of 8.99%.

Cresco Labs, Inc. has a consensus price target of $2.0000, signalling upside risk potential of 80.18%. On the other hand BioMarin Pharmaceutical, Inc. has an analysts' consensus of $88.87 which suggests that it could grow by 40.13%. Given that Cresco Labs, Inc. has higher upside potential than BioMarin Pharmaceutical, Inc., analysts believe Cresco Labs, Inc. is more attractive than BioMarin Pharmaceutical, Inc..

Cresco Labs, Inc. has a beta of 1.103, which suggesting that the stock is 10.297% more volatile than S&P 500. In comparison BioMarin Pharmaceutical, Inc. has a beta of 0.256, suggesting its less volatile than the S&P 500 by 74.362%.

Cresco Labs, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. BioMarin Pharmaceutical, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Cresco Labs, Inc. pays -- of its earnings as a dividend. BioMarin Pharmaceutical, Inc. pays out -- of its earnings as a dividend.

Cresco Labs, Inc. quarterly revenues are $164.9M, which are smaller than BioMarin Pharmaceutical, Inc. quarterly revenues of $786.8M. Cresco Labs, Inc.'s net income of -$22M is higher than BioMarin Pharmaceutical, Inc.'s net income of -$30.7M. Notably, Cresco Labs, Inc.'s price-to-earnings ratio is -- while BioMarin Pharmaceutical, Inc.'s PE ratio is 23.76x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Cresco Labs, Inc. is 0.58x versus 4.02x for BioMarin Pharmaceutical, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Savara, Inc. has a net margin of -13.32% compared to Cresco Labs, Inc.'s net margin of --. Cresco Labs, Inc.'s return on equity of -13.84% beat Savara, Inc.'s return on equity of -78.83%.

Cresco Labs, Inc. has a consensus price target of $2.0000, signalling upside risk potential of 80.18%. On the other hand Savara, Inc. has an analysts' consensus of $10.81 which suggests that it could grow by 89.03%. Given that Savara, Inc. has higher upside potential than Cresco Labs, Inc., analysts believe Savara, Inc. is more attractive than Cresco Labs, Inc..

Cresco Labs, Inc. has a beta of 1.103, which suggesting that the stock is 10.297% more volatile than S&P 500. In comparison Savara, Inc. has a beta of 0.336, suggesting its less volatile than the S&P 500 by 66.415%.

Cresco Labs, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Savara, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Cresco Labs, Inc. pays -- of its earnings as a dividend. Savara, Inc. pays out -- of its earnings as a dividend.

Cresco Labs, Inc. quarterly revenues are $164.9M, which are larger than Savara, Inc. quarterly revenues of --. Cresco Labs, Inc.'s net income of -$22M is higher than Savara, Inc.'s net income of -$29.6M. Notably, Cresco Labs, Inc.'s price-to-earnings ratio is -- while Savara, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Cresco Labs, Inc. is 0.58x versus -- for Savara, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Tilray Brands, Inc. has a net margin of -13.32% compared to Cresco Labs, Inc.'s net margin of -20%. Cresco Labs, Inc.'s return on equity of -13.84% beat Tilray Brands, Inc.'s return on equity of -98.18%.

Cresco Labs, Inc. has a consensus price target of $2.0000, signalling upside risk potential of 80.18%. On the other hand Tilray Brands, Inc. has an analysts' consensus of $11.83 which suggests that it could grow by 49.87%. Given that Cresco Labs, Inc. has higher upside potential than Tilray Brands, Inc., analysts believe Cresco Labs, Inc. is more attractive than Tilray Brands, Inc..

Cresco Labs, Inc. has a beta of 1.103, which suggesting that the stock is 10.297% more volatile than S&P 500. In comparison Tilray Brands, Inc. has a beta of 2.022, suggesting its more volatile than the S&P 500 by 102.181%.

Cresco Labs, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Tilray Brands, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Cresco Labs, Inc. pays -- of its earnings as a dividend. Tilray Brands, Inc. pays out -- of its earnings as a dividend.

Cresco Labs, Inc. quarterly revenues are $164.9M, which are smaller than Tilray Brands, Inc. quarterly revenues of $217.5M. Cresco Labs, Inc.'s net income of -$22M is higher than Tilray Brands, Inc.'s net income of -$43.5M. Notably, Cresco Labs, Inc.'s price-to-earnings ratio is -- while Tilray Brands, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Cresco Labs, Inc. is 0.58x versus 0.95x for Tilray Brands, Inc.. Usually stocks with elevated PS ratios are considered overvalued.